---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030356"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-08-28T23:59:59+00:00"
generated_at: "2026-06-11T02:54:12.833400+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncocyte's VitaGraft Kidney test receives Medicare coverage decision from Palmetto GBA

## Summary
- Palmetto GBA, a Medicare Administrative Contractor, issued final LCD for VitaGraft Kidney test.
- Test meets coverage criteria under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).
- Decision could enable Medicare reimbursement for Oncocyte's transplant rejection test.
- Coverage applies to beneficiaries under Palmetto GBA's jurisdiction.
- Oncocyte announced the decision in an August 28, 2023 press release.

## SEC filing metadata
- accession: 0001493152-23-030356
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-08-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223030356/0001493152-23-030356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223030356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030356
- JSON: https://secwatch.observer/filing/0001493152-23-030356.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.